212 Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint

British Journal of Cancer

Volumn 108, Issue 10, 2013, Pages 2013-2020

  Yong, K J ^a   Milenic, D E ^a   Baidoo, K E ^a   Brechbiel, M W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AURORA B KINASE; BUB1 RELATED PROTEIN; HISTONE H3; PACLITAXEL; TCMC TRASTUZUMAB PB 212; TRANSCRIPTION FACTOR E2F4; TRASTUZUMAB; UNCLASSIFIED DRUG; LEAD;

APOPTOSIS; ARTICLE; CELL CYCLE S PHASE; CELL KILLING; COLON CANCER; CONTROLLED STUDY; DNA CONTENT; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; MICRONUCLEUS; MITOSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOIMMUNOTHERAPY; TUMOR XENOGRAFT; ANIMAL; CELL DEATH; COLON TUMOR; DRUG EFFECT; DRUG SCREENING; FEMALE; METABOLISM; METHODOLOGY; MOUSE; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL DEATH; CELL LINE, TUMOR; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LEAD RADIOISOTOPES; M PHASE CELL CYCLE CHECKPOINTS; MICE; MICE, NUDE; PACLITAXEL; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MLCS; MLOWN;

EID: 84878550840     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.189     Document Type: Article

References (44)

1. Abal M, Andreu JM, Barasoain I (2003) Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 3: 193-203.
2. Agus DB, Bunn Jr PA, Franklin W, Garcia M, Ozols RF (2000) HER2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol 27: 53-63.
3. Andreassen PR, Lacroix FB, Lohez OD, Margolis RL (2001) Neither p21WAF1 nor 14-3-3sigma prevents G2 progression to mitotic catastrophe in human colon carcinoma cells after DNA damage, but p21WAF1 induces stable G1 arrest in resting tetraploid cells. Cancer Res 61: 7660-7668.
4. Asosingh K, De Raeve H, Van Riet I, Van Camp B, Vanderkerken K (2003) Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis. Blood 101: 3136-3141.
5. Bunz F, Dutriaux A, Lengauer C, Walsman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501.
6. Burke PA, DeNardo SJ, Miers LA, Kukis DL, DeNardo GL (2002) Combined modality radioimmunotherapy. Promise and peril. Cancer 94: 1320-1331.
7. Chappell LL, Dadachova E, Milenic DE, Gamestani K, Wu C, Brechbiel MW (2000) Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. Nucl Med Biol 27: 93-100.
8. Chen RH (2002) BubR1 is essential for kinetochore localization of other spindle checkpoint proteins and its phosphorylation requires Mad1 J Cell Biol 158: 487-496.
9. Chung HW, Bang SM, Park SW, Chung JB, Kang JK, Kim JW, Seong JS, Lee WJ, Song SY (2004) A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifuridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 60: 1494-1501.
10. Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM (2000) Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy. Clin Cancer Res 6: 3621-3628.
11. Crow DM, Williams L., Colcher D, Wong JY, Raubitschek A, Shively JE (2005) Combined radiotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with Taxol. Bioconjug Chem 16: 1117-1125.
12. Dadachova E, Chappell LL, Brechbiel MW(1999) Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. Nucl Med Biol 26: 977-982.
13. Dai W, Wang Q, Lin T, Swamy M, Fang Y, Xie S, Mahmood R, Yang YM, Rao CV (2004) Slippage of mitotic arrest and enhanced tumor development in mice with BubR1 haploinsufficiency. Cancer Res 64: 440-445.
14. Dickler A, Abrams RA (2005) Radiochemotherapy in the management of pancreatic cancer-Part II: use in adjuvant and locally unresectable settings. Semin Radiat Oncol 15: 235-244.
15. Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, Mortlock A, Keen N, Taylor SS (2003) Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 161: 267-280.
16. Fang Y, Liu T, Wang YM, Yang YM, Deng H, Kunicki J, Traganos F, Darzynkiewicz Z, Lu L, Dai W (2006) BurbR1 is involved in regulation of DNA damage responses. Oncogene 25: 3598-3605.
17. Friesen C, Glatting G, Koop B, Schwarz K, Morgenstern A, Apostolidis C, Debatin KM, Reske SN (2007) Breaking chemoresistance and radioresistance with 213Bi anti-CD45 antibodies in leukemia cells. Cancer Res 67: 1950-1958.
18. Gregoire V, Van NT, Stephens LC, Brock WA, Milas L, Plunkett W, Hittelman WN (1994) The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res 54: 6201-6209.
19. Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R, Heckel A, van Meel J, Rieder CL, Peters JM (2003) The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 161: 281-294.
20. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer Statistics, 2007. CA Cancer J Clin 57: 43-66.
21. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4: 253-265.
22. Kelly MP, Lee FT, Tahtis K, Smyth FE, Brechbiel MW, Scott AM (2007) Radioimmunotherapy with a-particle emitting 213Bi-C-funtionized transcyclohexyl-diethylentriaminepentacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy. Clin Cancer Res 13: 5604s-5612s.
23. Ko AH, Tempero MA (2005) Systemic therapy for pancreatic cancer. Semin Radiat Oncol 15: 245-253.
24. Lee EA, Keutmann MK, Dowling KL, Harris E, Chan G, Kao GD (2004) Inactivation of mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol Cancer Ther 3: 661-669.
25. Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D (2002) Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res 62: 5703-5710.
26. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB (1994) In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 86: 441-446.
27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
28. Meredith RF, Buchsbaum DJ, Alvarez RD, LoBuglio AF (2007) Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 13: 5643s-5645s.
29. Milas L, Hunter NR, Mason KA, Kurdoglu B, Peter LJ (1994) Enhancement of tumor radioresponse of murine mammary carcinoma by paclitaxel. Cancer Res 54: 3506-3510.
30. Milenic DE, Garmestani K, Brady ED, Albert PS, Abdulla A, Flynn J, Brechbiel MW (2007) Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease Clin Cancer Res 13: 1926-1935.
31. Milenic DE, Garmestani K, Brady ED, Baidoo KE, Albert PS, Wong KJ, Brechbiel MW (2008) Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease. Clin Cancer Res 14: 5108-5115.
32. Milenic DE, Garmestani K, Bardy ED, Albert PS, Ma D, Abdulla A, Brechbiel MW (2004) Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 10: 7834-7841.
33. Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, BrechbielMW (2005) Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a 212Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm 20: 557-568.
34. Milenic DE, Wong KJ, Baidoo KE, Nayak TK, Regino CA, Gamestani K, Brechbiel MW (2010) Targeting HER2: a report on the in vitro and in vivo preclinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials. Mabs 2: 550-564.
35. Ota T, Suto S, Katayama H, Han ZB, Suzuki F, Maeda M, Tanino M, Terada Y, Tatsuka M (2002) Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora B overexpression contributes to chromosome number instability. Cancer Res 62: 5168-5177.
36. Rodriguez M, Sevin BU, Perras J, Nauyen HN, Pham C, Stern AJ, Koechli OR, Averette HE (1995) Paclitaxel: a radiation sensitizer of human cervical cancer cells. Gynecol Oncol 57: 165-169.
37. Roninson IB, Broude EV, Chang BD (2001) If not apoptosis, then what? Treatment-induced mitotic catastrophe in tumor cells. Drug Resist Updat 4: 303-313.
38. Stephens LC, Ang KK, Schultheiss TE, Milas L, Meyn RE (1991) Apoptosis in irradiated murine tumors. Radiat Res 127: 308-316.
39. Steren A, Sevin BU, Perras J, Ramos R, Angioli R, Nguyen H, Koechli O, Averette HE (1993) Taxol as a radiation sensitizer: a flow cytometric study. Gynecol Oncol 50: 89-93.
40. Supiot S, Gouard S, Charrier J, Apostolidis C, Chatal JF, Barbet J, Davodeau F, Cherel M (2005) Mechanisms of cell sensitization to alpha radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines. Clin Cancer Res 11: 7047s-7052s.
41. Tom BH, Rutzky LP, Jakstys MM, Oyasu R, Kaye CI, Kahan BD (1976) Human colonic adenocarcinoma cells. I. Establishment and description of a new cell line. In Vitro 12: 180-191.
42. Yong K, Brechbiel MW (2011) Towards translation of 212Pb as a clinical therapeutic; getting the lead in! Dalton Trans 40: 6068-6076.
43. Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW (2012) 212Pb- Radioimmunotherapy induces G2 cell cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease. Mol Cancer Ther 11: 639-648.
44. Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW (2013) Sensitization of tumor to 212Pb-radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51. Int J Radiat Oncol Biol Phys 85: 1119-1126.